Breast cancer is a heterogeneously complex disease. A number of molecular subtypes with distinct biological features lead to different treatment responses and clinical outcomes.
Introduction
Breast cancer is the most common female malignancy in Taiwan and treatment outcomes have been improved enormously in the past decade, mainly with the wide applications of screening mammography (early detection at pre-clinical stage) and advancement in adjuvant/neoadjuvant therapy. Nowadays the selections of adjuvant therapy are determined from certain clinical predictive (also prognostic) factors such as estrogen receptor (ER) and human epidermal growth factor receptor type II (HER2) status. These factors not only determine which adjuvant therapy should be executed but also predict therapeutic responsiveness.
These conventional pathological factors, however, do not fully explain the prognostic heterogeneity observed within each clinical stratum [1] . For example, one-fourth of HER2 over-expressed breast tumors eventually develop resistance to trastuzumab while hormone manipulation therapy alone is not adequate for a subset of aggressive ER positive (luminal B) breast cancer. On the other hands, microarrays have subdivided breast cancers into molecular subtypes in terms of transcriptome profiles, such as the 'intrinsic subtype' proposed by the Stanford/University of North Carolina group. Initially Perou et al. identified 476 intrinsic genes from 65 breast cancers and healthy individuals; four subclasses: basal-like, Erb-B2+, normal breast-like, and luminal epithelial/ER+ were revealed through clustering analysis [1, 2] . The luminal subtype was further divided into luminal A and B, with the latter experienced worse survival [3] . Intrinsic genes were selected genes with the highest variations among different breast cancer patients but with the least variations within the same individual. Different generations of intrinsic signatures followed, and the latest prediction analysis of microarray 50 gene set (PAM50) was advised to provide prognostic and predictive values independent of traditional prognostic factors [4, 5] . The rationale underpinning the merits of molecular biomarkers rather than conventional pathological factors may result from that transcriptional aberrations essential for breast cancer pathogenesis are investigated, while clinical predictors are merely manifesting phenotypes.
During the 2011 St. Gallen experts' panel, immunohistochemical (IHC) surrogates for breast cancer molecular subtypes using tumor grade instead of Ki-67 had demonstrated that gene expression microarrays-defined breast cancer molecular subtypes could be approximated by conventional IHC assays [2] ; hormone receptor positive breast cancers are categorized into luminal A (HER2-and Ki-67<14% or nuclear grade I/II), luminal B1 (HER2-and Ki-67>14% or nuclear grade III), and luminal B2 (HER2+). Luminal B breast cancer tends to display a more aggressive and compromised clinical outcomes, and this subtype is presented as ER+ tumors with low progesterone receptor expression, high proliferation, high grade, and less responsive to hormone manipulation therapy [3] .
Artificial intelligence (AI) plays a crucial role in biomedical image analysis and cancer research. Certain breast carcinomas behave aggressively resulting in increased patient morbidity and poor patient prognosis. There are distinguishable cytological features of such tumors including aggressive variants of hereditary breast carcinoma, poorly differentiated metaplastic carcinoma, and triple negative breast cancer. BRCA1-associated breast cancers are commonly poorly differentiated, have "medullary features" (a syncytial growth pattern with pushing margins and a lymphocytic response), and are biologically very similar to basal-like subtype defined by gene expression profiling. BRCA2-associated breast cancers also tend to be relatively poorly differentiated but are more often ER-positive than BRCA1 mutant counterparts. With the utility of digitalized, whole-slide images, it is possible to develop an algorithm by artificial intelligence. A machine-learning algorithm may be applied to histopathological images of breast cancer specimens to see if it could pick out distinguishing patterns. Therefore, it is an urgent necessity in applying computer aided enhancement of breast pathological imaging diagnosis which could augment the performance of diagnostic accuracy, reducing both false positive results and negativities. Consequently, it would be of great help to scientific communities and clinical practitioners if molecular gene expression-defined molecular subtypes could be identified by pathology pattern recognition. In the present study, we aim to classify the molecular subtypes of breast cancer via pathogical images by deep convolutional neural network and transfer learning with pre-traine model such as ResNet50, InceptionV3, and VGG16.
Materials and methods
Two training strategies for specific subtype classification were established. The former approach used patches generated from whole slides image as training data. The latter would use an althernative approach which mounts the whole slide image for training ( Figure 1 ). The second approach would only require gene expression assay results for the final molecular subtyping, thus it may help pathologists spend less time in annotation.
Regarding molecular subtypes, 1218 whole slide images from TCGA-BRCA dataset were used to classify patients based on their mRNA expression profiles using genefu package in R software. The mRNA expression data of TCGA-BRCA was obtained from UCSC Xena database (https://xenabrowser.net/datapages/). We designed 2 strategies for the training based on different types of samples input including whole slide image based and patches-based. The former used whole slide image from diagnostic slides whereas the latter used patching method to generate patches at 256x256 and 128x128 pixel size. These samples were the input for transfer learning process and finally undergone artificial neural network for classification and output the prediction result. This model output is the subtypes of pathological images and their tumor locations.
Patch generation
A total of 1218 whole slides images from distinct molecular subtypes of breast cancer underwent patch generation with py-wsi (https://github.com/ysbecca/py-wsi). Py-wsi is a python-based tool allowing us to query the whole slide resolution at different level, the level tile and level dimension. In our study, we use py-wsi package to generate patches size of 256x256 pixel and 128x128 pixel at level 17 which is the highest resolution level.
Whole slide image preparation
The whole slide tissue were scanned with Aperio scanncer (Leica Biosystems, IL) to generated the digital file with .svs format. The .svs files were mounted at the highest resolution and used as training samples.
General design
The general design of our deep convolution neural network included two stages. The first stage applied transfer learning techniques which take advantages of state of the art pre-trained models such as ResNet50 [4] , InceptionV3 [5] , and VGG16 [6] for potential useful features 
Transfer learninng
Transfer learning with ResNet50 and VGG16 was carried out. The top layers of these models were not included in the feature extraction process, only convolutional layers were used. The input images were reshaped as default setting at 224x224 pixel for ResNet50 and VGG16.
The feature files were exported with different dimension depending on model output.
The output dimensions of each model were displayed in Table 1 . Table 1 . Features dimensions produced by VGG16, ResNet50 and InceptionV3 with patch-size of 256x256 pixel and 128x128 pixel.
Training procedures
Data were divided into 80% for training (training and validation set) and 20% for testing. The testing data was only used when the training was completed to prevent information leaking to the network.
The feature map files from Resnet50, InceptionV3 and VGG16 were used as input to artificial neural network with 4 hidden layers, each contains 512 neurons. The final connected layer linked to the output layer with 5 neurons, where each neuron represented one molecular subtype. We used stochastic gradient descent (SGD) as the optimizer with learning rate at 10e -5 together with a decay rate 10e -5 /10 for 10 epochs with the batch size set to 128. Kernel was used with rectified activation unit (ReLu) function with kernel initnitializer was "he_uniform". At the end of training, we used predict_generator to test the model perfomance with test data. The classification reported from scikit learn [9] was used to calculate and display the final classifications of each breast cancer molecular subtype with precision, recall, and F1score. All training was done with Tensorflow version 2.0 (Google Inc., Mountain View, CA).
The hardware system contained 2 GPU GeForce GTX 1080 Ti.
Results
We Table 2 ). These patches were fetched into the ResNet50 for feature extraction and trained with artificial neural network.
Performance of the pilot study was beyond 78% for validation accuracy with Resnet50
as the feature extractor. The results of VGG16 and InceptionV3 were still under working. We were currently working on the whole TCGA-BRCA dataset to boost the model performance. 
Discussion
Different breast cancer molecular subtypes have discrepant prognoses over time.
Understanding different recurrence patterns can improve breast cancer care through surveillance guidelines and result in the most optimistic treatment [10] . According to Metzger- reported that luminal A displayed a slow risk increase, reaching its maximum after three years and then remained steady. Luminal B presented most of its relapses during the first five years [11] . Compared with HER2+ and triple negative cancers, ER+ breast cancers experienced more mid-to long-term relapses, and acquired ESR1 mutations, resulting in ligand-independent and constitutive activation of ER, are believed to play a major role for late recurrence and hormone manipulation therapy resistance [12] .
Deciphering breast cancer molecular subtypes by deep learning approach could provide convenient and efficient way for diagnosis and treatment of breast cancer patients. It could reduce the spending budget of transcriptional profiling and subtyping discrepancy between IHC assays and mRNA expressions. In term of academic development, this is a novel approach which can lay the foundation for later research on breast cancer taxonomy and precision medicine.
We are approaching an era for artificial intelligence and machine learning-aided diagnosis and treatment. We believe that breast pathology imaging may be one of the frontiers.
Artificial intelligence has the potential to transform genomics, pathology, and breast oncology to the next level, and current deep learning systems are going to match human performance in reading pathological morphological features and reducing inter-observer variability.
In current study, the first approach with ResNet50 as the feature extractor archived an overall accuracy of 78% in the testing data whereas the model with InceptionV3 had 45% accuracy. The second approach results using whole slide image will be updated in the next revision.
In previous literatures, many models have been developed to predict or classify a wide range of diagnostic or therapeutic targets of breast cancer. in classifying ER+ and ER− patients [16] .
Conclusions
In summary, our present study provided a prqctical pipeline to use pathological images by deep convolutional neural network for breast cancer molecular subtypes with high accuracy. The trained model could be used to localize the tumor location in the whole slide image. In our experiment, the model with pre-trained model namely ResNet50 had the highest accuracy.
